Nano vesicular lipid carriers of angiotensin II receptor blocker: Anti-hypertensive and skin toxicity study in focus

References

• Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Akhtar N, Raish M, Aqil M. 2014a. Systemic delivery of beta-blockers via transdermal route for hypertension. Saudi Pharm J. published online 3 January 2014, doi: 10.1016/j.jsps.2013.12.019.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Aqil M, Kohli K. 2013a. Transdermal delivery of calcium channel blockers for hypertension. Expert Opin Drug Deliv. 10:1137–1153.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Mohizea AM, Al-Jenoobi FI, Aqil M. 2014b. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. Drug Deliv. Posted online on July 28, 1–12.
   Google Scholar
• Ahad A, Aqil M, Ali A. 2014c. Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole. Int J Biol Macromol. 64:144–149.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Chaudhary H, Sultana Y, Mujeeb M, Talegaonkar S. 2009. Chemical penetration enhancers: a patent review. Expert Opin Ther Pat. 19:969–988.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M. 2013b. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. Int J Pharm. 443:26–38.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M. 2014d. Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: Preclinical assessment of pharmacokinetic in wistar albino rats. Expert Opin Drug Deliv. 11:1149–1162.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. 2010. Transdermal drug delivery: the inherent challenges and technological advancements. Asian J Pharm Sci. 5:276–288.
   Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. 2011. Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride. Curr Drug Deliv. 8:213–224.
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. 2012. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 8:237–249.
   PubMed Web of Science ®Google Scholar
• Ahad A, Raish M, Al-Mohizea AM, Al-Jenoobi FI, Alam MA. 2014e. Enhanced anti-inflammatory activity of carbopol loaded meloxicam nanoethosomes gel. Int J Biol Macromol. 67:99–104.
   PubMed Web of Science ®Google Scholar
• Akhtar N. 2014. Vesicles: a recently developed novel carrier for enhanced topical drug delivery. Curr Drug Deliv. 11:87–97.
   PubMed Web of Science ®Google Scholar
• Alexander A, Dwivedi S, Ajazuddin, Giri TK, Saraf S, Tripathi DK. 2012. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 164:26–40.
   PubMed Web of Science ®Google Scholar
• Amin S, Sarfenejad A, Ahmad J, Kohli K, Mir SR. 2013. Nanovesicular transfersomes for enhanced systemic delivery of telmisartan. Adv Sci Eng Med. 5:299–308.
   Google Scholar
• An K, Sun Y, Wu Y, Yuan H, Cui Z, Xu L. 2013. Preparation and in vitro percutaneous penetration of simvastatin ethosome gel. Artif Cells Nanomed Biotechnol. 41:315–318.
   PubMed Web of Science ®Google Scholar
• An K, Sun Y, Xu L, Cui X. 2011. Preparation and in vitro evaluation of simvastatin ethosome. Artif Cells Blood Substit Immobil Biotechnol. 39:347–350.
   PubMed Web of Science ®Google Scholar
• Aqil M, Ahad A, Sultana Y, Ali A. 2007. Status of terpenes as skin penetration enhancers. Drug Discov Today. 12:1061–1067.
   PubMed Web of Science ®Google Scholar
• Aqil M, Ali A, Sultana Y, Dubey K, Najmi AK, Pillai KK. 2006a. In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note. AAPS PharmSciTech. 7:E6.
   Google Scholar
• Aqil M, Ali A, Sultana Y, Parvez N. 2004a. Communication: Matrix type transdermal drug delivery systems of metoprolol tartrate: skin toxicity and in vivo characterization. Ethiop Pharm J. 22:53–60.
   Google Scholar
• Aqil M, Sultana Y, Ali A. 2006b. Transdermal delivery of beta-blockers. Expert Opin Drug Deliv. 3:405–418.
   PubMed Web of Science ®Google Scholar
• Aqil M, Sultana Y, Ali A, Dubey K, Najmi AK, Pillai KK. 2004b. Transdermal drug delivery systems of a beta blocker: design, in vitro, and in vivo characterization. Drug Deliv. 11:27–31.
   PubMed Web of Science ®Google Scholar
• Babu RJ, Pandit JK. 2005. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int J Pharm. 288:325–334.
   PubMed Web of Science ®Google Scholar
• Bairwa M, Pilania M, Gupta V, Yadav K. 2013. Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother. 10:708–713.
   PubMed Web of Science ®Google Scholar
• Basile JN. 2003. Optimizing antihypertensive treatment in clinical practice. Am J Hypertens. 16:13S–17S.
   Google Scholar
• Berkow SE, Barnard ND. 2005. Blood pressure regulation and vegetarian diets. Nutr Rev. 63:1–8.
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Campbell NR, Fodor JG. 2006. Worldwide epidemic of hypertension. Can J Cardiol. 22:553–555.
   PubMed Web of Science ®Google Scholar
• Draize JH, Woodard G, Calvery HO. 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 82:377–390.
   Web of Science ®Google Scholar
• Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. 2007a. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 123:148–154.
   PubMed Web of Science ®Google Scholar
• Dubey V, Mishra D, Jain NK. 2007b. Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm. 67:398–405.
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Williams AC. 2009. Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv. 6:149–163.
   PubMed Web of Science ®Google Scholar
• Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. 2006. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 322:60–66.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. 2014. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 129: e28–e292.
   Web of Science ®Google Scholar
• Goindi S, Dhatt B, Kaur A. 2014. Ethosomes-based topical delivery system of antihistaminic drug for treatment of skin allergies. J Microencapsul. 31:716–724.
   PubMed Web of Science ®Google Scholar
• Gungor S, Ozsoy Y. 2012. Systemic delivery of antihypertensive drugs via skin. Ther Deliv. 3:1101–1116.
   PubMedGoogle Scholar
• Harries C, Armstrong I. 2012. A review of the management of pulmonary arterial hypertension associated with congenital heart disease. Eur J Cardiovasc Nurs. 11:239–247.
   PubMed Web of Science ®Google Scholar
• Jain R, Aqil M, Ahad A, Ali A, Khar RK. 2008. Basil oil is a promising skin penetration enhancer for transdermal delivery of labetolol hydrochloride. Drug Dev Ind Pharm. 34:384–389.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 2005. Global burden of hypertension: analysis of worldwide data. Lancet. 365:217–223.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. 2004. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 22:11–19.
   PubMed Web of Science ®Google Scholar
• Lake Y, Pinnock S. 2000. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch. Aust N Z J Obstet Gynaecol. 40:313–316.
   PubMed Web of Science ®Google Scholar
• Mbah CC, Builders PF, Attama AA. 2014. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus. Expert Opin Drug Deliv. 11:45–59.
   PubMed Web of Science ®Google Scholar
• Mura S, Manconi M, Fadda AM, Sala MC, Perricci J, Pini E, Sinico C. 2013. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil: in vitro evaluation of drug permeation by infrared spectroscopy. Pharm Dev Technol. 18:1339–1345.
   PubMed Web of Science ®Google Scholar
• Ragan C. 1953. Corticotropin, cortisone and related steroids in clinical medicine; practical considerations. Bull N Y Acad Med. 29:355–376.
   PubMedGoogle Scholar
• Ralston RA, Lee JH, Truby H, Palermo CE, Walker KZ. 2012. A systematic review and meta-analysis of elevated blood pressure and consumption of dairy foods. J Hum Hypertens. 26:3–13.
   PubMed Web of Science ®Google Scholar
• Saroha K, Yadav B, Sharma B. 2011. Transdermal patch: A discrete dosage form. Int J Curr Pharm Res. 3:98–108.
   Google Scholar
• Selvam RP, Singh AK, Sivakumar T. 2010. Transdermal drug delivery systems for antihypertensive drugs - A review. Int J Pharm Biomed Res. 1:1–8.
   Google Scholar
• Shams MS, Alam MI, Ali A, Sultana Y, Aqil M. 2010. Pharmacodynamics of a losartan transdermal system for the treatment of hypertension. Drug Dev Ind Pharm. 36:385–392.
   PubMed Web of Science ®Google Scholar
• Singh D, Pradhan M, Nag M, Singh MR. 2014. Vesicular system: Versatile carrier for transdermal delivery of bioactives. Artif Cells Nanomed Biotechnol. published online 25 February 2015, doi: 10.3109/21691401.2014.883401.
   Google Scholar
• Sinha VR, Kaur MP. 2000. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm. 26:1131–1140.
   PubMed Web of Science ®Google Scholar
• Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. 2012. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 92:299–304.
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. 2000. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 65:403–418.
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Levi-Schaffer F, Pilipoponsky A. 1998. Novel lipid vesicular system for enhanced delivery. J Lipid Res. 8:113–114.
   Google Scholar
• Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. 2001. Intracellular delivery mediated by an ethosomal carrier. Biomaterials. 22:3053–3059.
   PubMed Web of Science ®Google Scholar
• Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. 2007. Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech. 8:2.
   PubMed Web of Science ®Google Scholar
• Verma P, Pathak K. 2010. Therapeutic and cosmeceutical potential of ethosomes: an overview. J Adv Pharm Technol Res. 1:274–282.
   PubMedGoogle Scholar
• Verma P, Pathak K. 2012. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine. 8:489–496.
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. 2004. Penetration enhancers. Adv Drug Deliv Rev. 56:603–618.
   PubMed Web of Science ®Google Scholar